Pancreatic Cancer Research

ResearcherJiangnan UniversityNo recent work listed

Hao Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7983-7377; OpenAlex author ID A5077836229. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 3 papers

Papers 12

  1. Vav1-dependent Rac1 activation mediates hypoxia-induced gemcitabine resistance in pancreatic ductal adenocarcinoma cells through upregulation of HIF-1α express… First author DOI 10.1002/cbin.12074↗
  2. Linc-UROD stabilizes ENO1 and PKM to strengthen glycolysis, proliferation and migration of pancreatic cancer cells. Co-author DOI 10.1016/j.tranon.2022.101583↗
  3. Linc00662 m6A promotes the progression and metastasis of pancreatic cancer by activating focal adhesion through the GTF2B-ITGA1-FAK pathway. Last author PMID 37293163↗
  4. UBE2C promotes the progression of pancreatic cancer and glycolytic activity via EGFR stabilization-mediated PI3K-Akt pathway activation. Co-author DOI 10.21037/jgo-22-516↗
  5. Validation and modification of the AJCC 8th TNM staging system for pancreatic ductal adenocarcinoma in a Chinese cohort: A nationwide pancreas data center anal… Co-author DOI 10.21147/j.issn.1000-9604.2021.04.03↗
  6. [The comparison of prognosis factors after radical resection for pancreatic ductal adenocarcinoma between China Pancreas Data Center and SEER database]. Co-author DOI 10.3760/cma.j.cn112139-20210507-00202↗
  7. Predicting early recurrence for resected pancreatic ductal adenocarcinoma: a multicenter retrospective study in China. Co-author PMID 34249444↗
  8. Long non-coding RNA lnc-PCTST predicts prognosis through inhibiting progression of pancreatic cancer by downregulation of TACC-3. Co-author DOI 10.1002/ijc.31657↗
  9. Long non-coding RNA XLOC_000647 suppresses progression of pancreatic cancer and decreases epithelial-mesenchymal transition-induced cell invasion by down-regul… Co-author DOI 10.1186/s12943-018-0761-9↗
  10. micorRNA-101 silences DNA-PKcs and sensitizes pancreatic cancer cells to gemcitabine. Co-author DOI 10.1016/j.bbrc.2016.12.074↗
  11. Interplay between menin and Dnmt1 reversibly regulates pancreatic cancer cell growth downstream of the Hedgehog signaling pathway. Co-author DOI 10.1016/j.canlet.2015.09.019↗
  12. DNA-PKcs is important for Akt activation and gemcitabine resistance in PANC-1 pancreatic cancer cells. Co-author DOI 10.1016/j.bbrc.2014.08.059↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yinmo Yang · 3 shared papers, 2021 · strength 0.44
  2. Xiaodong Tian · 3 shared papers, 2021 · strength 0.44
  3. Congyuan Zhu · 2 shared papers, 2014–2023 · strength 0.28
  4. Weikang Liu · 2 shared papers, 2021 · strength 0.25
  5. Ye Ma · 1 shared paper, 2023 · strength 0.24
  6. Dongming Zhu · 1 shared paper, 2023 · strength 0.24
  7. Yuan Ming He · 3 shared papers, 2017–2018 · strength 0.22
  8. Yandong Wang · 3 shared papers, 2017–2018 · strength 0.22
  9. Yuan He · 1 shared paper, 2023 · strength 0.17
  10. Changhong Lian · 1 shared paper, 2023 · strength 0.17
  11. Changyong Zhao · 1 shared paper, 2023 · strength 0.17
  12. Minfeng Liu · 1 shared paper, 2023 · strength 0.17
  13. Tiantian Lai · 1 shared paper, 2023 · strength 0.17
  14. Shuo Zhang · 1 shared paper, 2023 · strength 0.17
  15. Junjing Zhou · 1 shared paper, 2023 · strength 0.17
  16. Xiaowen Su · 1 shared paper, 2023 · strength 0.17
  17. Jingzhu Cao · 1 shared paper, 2022 · strength 0.16
  18. Chenming Ni · 1 shared paper, 2022 · strength 0.16
  19. Liu Ouyang · 1 shared paper, 2022 · strength 0.16
  20. Gang Nie · 1 shared paper, 2022 · strength 0.16
  21. Zipeng Lu · 2 shared papers, 2018 · strength 0.14
  22. Tianfang Xia · 2 shared papers, 2018 · strength 0.14
  23. Guodong Shi · 2 shared papers, 2018 · strength 0.14
  24. Hao Yuan · 2 shared papers, 2018 · strength 0.14
  25. Dongfang Liu · 2 shared papers, 2018 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.